Please use this identifier to cite or link to this item:
|Title:||Carbapenemase Inhibitors: Updates on Developments in 2021||Authors:||Zerdan, Maroun Bou
Hassan, Sally Al
Hajjar, Rayan El
Zerdan, Morgan Bou
|Affiliations:||Faculty of Medicine||Keywords:||Carbapenem resistance
|Issue Date:||2022-07||Part of:||Journal of Clinical Medicine Research||Volume:||14||Issue:||7||Start page:||251||End page:||259||Abstract:||
Carbapenem resistance, an emerging global health problem, compromises the treatment of infections caused by nosocomial pathogens. Preclinical and clinical trials demonstrate that a new generation of carbapenemases inhibitors, together with the recently approved avi-bactam, relebactam and vaborbactam, would address this resistance. Our review summarizes the latest developments related to carbap-enemase inhibitors synthesized to date, as well as their spectrum of activity and their current stage of development. A particular focus will be on β-lactam/β-lactamase inhibitor combinations that could potentially be used to treat infections caused by carbapenemase-producer pathogens. These new combinations mark a critical step forward the fight against antimicrobial resistance.
|URI:||https://scholarhub.balamand.edu.lb/handle/uob/6001||ISSN:||19183003||DOI:||10.14740/jocmr4764||Open URL:||Link to full text||Type:||Journal Article|
|Appears in Collections:||Faculty of Medicine|
Show full item record
checked on Dec 2, 2023
checked on Dec 1, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.